HLA-DR: Molecular insights and vaccine design

Current Pharmaceutical Design

Volumn 15, Issue 28, 2009, Pages 3249-3261

  Stern, Lawrence J ^a   Calvo Calle, J Mauricio ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DM ANTIGEN; HLA DP ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MALARIA VACCINE; PEPTIDE VACCINE;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL SELECTION; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; EPITOPE MAPPING; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PARASITE IMMUNITY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; REVIEW; SPOROZOITE; VACCINATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; EPITOPES; GENES, MHC CLASS II; HLA-DR ANTIGENS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; VACCINES; VACCINES, SUBUNIT;

EID: 70449426373     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105171     Document Type: Review

References (105)

1. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4: 316-319
2. Lambkin R, Novelli P, Oxford J, Gelder C. Human genetics and responses to influenza vaccination: clinical implications. Am J Pharmacogenomics 2004; 4: 293-298 (Pubitemid 39452416)
3. Molano A, Park SH, Chiu YH, Nosseir S, Bendelac A, Tsuji M. Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses. J Immunol 2000; 164: 5005-5009 (Pubitemid 30305169)
4. Oliveira GA, Kumar KA, Calvo-Calle JM, Othoro C, Altszuler D, Nussenzweig V, et al. Class II-restricted protective immunity induced by malaria sporozoites. Infect Immun 2008; 76: 1200-1206
5. Xu R, Johnson AJ, Liggitt D, Bevan MJ. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004; 172: 6265-6271 (Pubitemid 38621233)
6. Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, Johnston RJ, et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008; 28: 847-858 (Pubitemid 351778408)
7. Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 2008; 8: 1659-1667
8. Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. Vaccine 2008; 26: 6183-6188
9. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008; 121: e1091-9.
10. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47: 401-409
11. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2: 706-713
12. Nardin EH, Calvo-Calle JM, Oliveira GA, Nussenzweig RS, Schneider M, Tiercy JM, et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 2001; 166: 481-489 (Pubitemid 32038467)
13. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003; 300: 337-339 (Pubitemid 36433726)
14. Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat Med 2002; 8: 166-170 (Pubitemid 34155128)
15. Kemball CC, Pack CD, Guay HM, Li ZN, Steinhauer DA, Szomolanyi-Tsuda E, et al. The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection. J Immunol 2007; 179: 1113-1121
16. Marzo AL, Vezys V, Klonowski KD, Lee SJ, Muralimohan G, Moore M, et al. Fully functional memory CD8 T cells in the absence of CD4 T cells. J Immunol 2004; 173: 969-975 (Pubitemid 38924270)
17. van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr Opin Immunol 2008; 20: 339-343
18. Johnson AJ, Chu CF, Milligan GN. Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J Virol 2008; 82: 9678-9688
19. Elyaman W, Kivisakk P, Reddy J, Chitnis T, Raddassi K, Imitola J, et al. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol 2008; 173: 411-422
20. Tsuji M, Romero P, Nussenzweig RS, Zavala F. CD4+ cytolytic T cell clone confers protection against murine malaria. J Exp Med 1990; 172: 1353-1357 (Pubitemid 20366210)
21. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18: 349-356
22. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028. (Pubitemid 40563191)
23. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, et al. Predominant naturally processed peptides bound to HLADR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992; 358: 764-768
24. Reich EP, von Grafenstein H, Barlow A, Swenson KE, Williams K, Janeway CA, Jr. Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. J Immunol 1994; 152: 2279-2288 (Pubitemid 24097918)
25. Malnati MS, Marti M, LaVaute T, Jaraquemada D, Biddison W, DeMars R, et al. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 1992; 357: 702-704
26. Nedjic J, Aichinger M, Mizushima N, Klein L. Macroauto-phagy, endogenous MHC II loading and T cell selection: the benefits of breaking the rules. Curr Opin Immunol 2009; 21: 92-97
27. Strawbridge AB, Blum JS. Autophagy in MHC class II antigen processing. Curr Opin Immunol 2007; 19: 87-92.
28. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 1992; 10: 13-49.
29. Guardiola J, Maffei A. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Crit Rev Immunol 1993; 13: 247-268 (Pubitemid 2030717)
30. Ovsyannikova IG, Dhiman N, Jacobson RM, Poland GA. Human leukocyte antigen polymorphisms: variable humoral immune responses to viral vaccines. Expert Rev Vaccines 2006; 5: 33-43.
31. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 2006; 193: 655-663
32. Guerau-de-Arellano M, Huber BT. Development of autoimmunity in Lyme arthritis. Curr Opin Rheumatol 2002; 14: 388-393
33. Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, et al. Proliferative and cytokine responses to class II HER- 2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998; 4: 2015-2024 (Pubitemid 28369189)
34. Rohn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, et al. A novel strategy for the discovery of MHC class IIrestricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 2005; 65: 10068-10078 (Pubitemid 41541489)
35. Ovsyannikova IG, Vierkant RA, Poland GA. Importance of HLADQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides. Vaccine 2006; 24: 5381-5389
36. Poland GA, Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001; 20: 430-438
37. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006; 78: 169-177
38. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998; 51: 593-604. (Pubitemid 28306463)
39. Kruger A, Adams P, Hammer J, Bocher WO, Schneider PM, Rittner C, et al. Hepatitis B surface antigen presentation and HLADRB1*- lessons from twins and peptide binding studies. Clin Exp Immunol 2005; 140: 325-332 (Pubitemid 40559160)
40. Mustafa AS. HLA-restricted immune response to mycobacterial antigens: relevance to vaccine design. Hum Immunol 2000; 61: 166-171
41. Shams H, Klucar P, Weis SE, Lalvani A, Moonan PK, Safi H, et al. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J Immunol 2004; 173: 1966-1977 (Pubitemid 38971633)
42. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci USA 1996; 93: 734-738
43. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995; 13: 587-622.
44. Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ, Stern LJ. A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition. Proc Natl Acad Sci USA 2004; 101: 13279-13284 (Pubitemid 39209656)
45. Parry CS, Gorski J, Stern LJ. Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity. J Mol Biol 2007; 371: 435-446 (Pubitemid 47048269)
46. Li Y, Li H, Martin R, Mariuzza RA. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 2000; 304: 177-188
47. u. Immunity 2002; 17: 83-94.
48. Lovitch SB, Unanue ER. Conformational isomers of a peptide-class II major histocompatibility complex. Immunol Rev 2005; 207: 293-313. (Pubitemid 41415025)
49. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219 (Pubitemid 30099526)
50. Rohn TA, Boes M, Wolters D, Spindeldreher S, Muller B, Langen H, et al. Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization. Nat Immunol 2004; 5: 909-918 (Pubitemid 39276235)
51. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. Precise prediction of major histocompatibility complex class IIpeptide interaction based on peptide side chain scanning. J Exp Med 1994; 180: 2353-2358 (Pubitemid 24351618)
52. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17: 555-561 (Pubitemid 29262918)
53. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001; 17: 1236-1237 (Pubitemid 33735355)
54. Anderson MW, Gorski J. Cooperativity during the formation of peptide/MHC class II complexes. Biochemistry 2005; 44: 5617-5624 (Pubitemid 40525099)
55. Zavala-Ruiz Z, Strug I, Anderson MW, Gorski J, Stern LJ. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Chem Biol 2004; 11: 1395-1402 (Pubitemid 39351376)
56. Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog 2007; 3: 1511-1529 (Pubitemid 350085615)
57. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, et al. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005; 57: 304-314 (Pubitemid 40905049)
58. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007; 8: 238. (Pubitemid 47225391)
59. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002; 63: 701-709 (Pubitemid 34983301)
60. Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V. MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Res 2005; 33: W172-9. (Pubitemid 44529903)
61. Fleckenstein B, Kalbacher H, Muller CP, Stoll D, Halder T, Jung G, et al. New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. Eur J Biochem 1996; 240: 71-77
62. Hammer J, Belunis C, Bolin D, Papadopoulos J, Walsky R, Higelin J, et al. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc Natl Acad Sci USA 1994; 91: 4456-4460 (Pubitemid 24143452)
63. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, et al. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 2008; 4: e1000107.
64. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005; 3: e91. (Pubitemid 40605287)
65. Geluk A, van Meijgaarden KE, Schloot NC, Drijfhout JW, Ottenhoff TH, Roep BO. HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes 1998; 47: 1594-1601 (Pubitemid 28445347)
66. Texier C, Pouvelle-Moratille S, Busson M, Charron D, Menez A, Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur J Immunol 2001; 31: 1837-1846 (Pubitemid 32547346)
67. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008; 4: e1000048. (Pubitemid 351656722)
68. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008; 9 Suppl 12: S22.
69. McFarland BJ, Beeson C. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med Res Rev 2002; 22: 168-203. (Pubitemid 34160584)
70. Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, Weaver JM, et al. The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance. Immunity 2005; 23: 29-40. (Pubitemid 41019655)
71. Belmares MP, Busch R, Wucherpfennig KW, McConnell HM, Mellins ED. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol 2002; 169: 5109-5117
72. Strug I, Calvo-Calle JM, Green KM, Cruz J, Ennis FA, Evans JE, et al. Vaccinia peptides eluted from HLA-DR1 isolated from virusinfected cells are recognized by CD4+ T cells from a vaccinated donor. J Proteome Res 2008; 7: 2703-2711
73. Malaria WG, Programme. World malaria report 2008 World Health Organization 2008.
74. Doolan DL, Southwood S, Freilich DA, Sidney J, Graber NL, Shatney L, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci USA 2003; 100: 9952-9957 (Pubitemid 37087049)
75. Audibert F, Jolivet M, Chedid L, Arnon R, Sela M. Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci USA 1982; 79: 5042-5046
76. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987; 328: 257-259
77. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988; 332: 158-161
78. Etlinger HM, Felix AM, Gillessen D, Heimer EP, Just M, Pink JR, et al. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J Immunol 1988; 140: 626-633 (Pubitemid 18056794)
79. Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984; 225: 593-599 (Pubitemid 14053761)
80. Weber JL, Hockmeyer WT. Structure of the circumsporozoite protein gene in 18 strains of Plasmodium falciparum. Mol Biochem Parasitol 1985; 15: 305-316
81. Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, et al. Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull World Health Organ 1990; 68 (Suppl): 33-37
82. Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Matile H, Etlinger H, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988; 336: 778-780 (Pubitemid 19014438)
83. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 1985; 317: 359-361 (Pubitemid 15232524)
84. Guillet JG, Lai MZ, Briner TJ, Smith JA, Gefter ML. Interaction of peptide antigens and class II major histocompatibility complex antigens. Nature 1986; 324: 260-262 (Pubitemid 17180454)
85. Buus S, Colon S, Smith C, Freed JH, Miles C, Grey HM. Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci USA 1986; 83: 3968-3971
86. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19: 2237-2242 (Pubitemid 20024747)
87. Busch R, Strang G, Howland K, Rothbard JB. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol 1990; 2: 443-451 (Pubitemid 20170085)
88. O'Sullivan D, Sidney J, Appella E, Walker L, Phillips L, Colon SM, et al. Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 1990; 145: 1799-1808 (Pubitemid 20336747)
89. Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Sinigaglia F, et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 1993; 151: 489-499 (Pubitemid 23207014)
90. Panina-Bordignon P, Demotz S, Corradin G, Lanzavecchia A. Study on the immunogenicity of human class-II-restricted T-cell epitopes: processing constraints, degenerate binding, and promiscuous recognition. Cold Spring Harb Symp Quant Biol 1989; 54 Pt 1: 445-451 (Pubitemid 20177614)
91. Kilgus J, Jardetzky T, Gorga JC, Trzeciak A, Gillessen D, Sinigaglia F. Analysis of the permissive association of a malaria T cell epitope with DR molecules. J Immunol 1991; 146: 307-315
92. Murthy VL, Stern LJ. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure 1997; 5: 1385-1396
93. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res 1998; 18: 79-92. (Pubitemid 28554760)
94. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1: 751-761
95. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-inoil emulsion. Vaccine 2006; 24: 5235-5244 (Pubitemid 43818188)
96. Bettahi I, Dasgupta G, Renaudet O, Chentoufi AA, Zhang X, Carpenter D, et al. Antitumor activity of a self-adjuvanting glycolipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol Immunother 2009; 58: 187-200.
97. Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999; 162: 3088-3095 (Pubitemid 29309340)
98. Nielsen FS, Sauer J, Backlund J, Voldborg B, Gregorius K, Mouritsen S, et al. Insertion of foreign T cell epitopes in human tumor necrosis factor alpha with minimal effect on protein structure and biological activity. J Biol Chem 2004; 279: 33593-33600 (Pubitemid 39063008)
99. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from betaamyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005; 174: 1580-1586
100. Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Iyengar S, Harro C, et al. Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J Immunol 2006; 176: 3753-3759 (Pubitemid 43364022)
101. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1: 209-219 (Pubitemid 33741959)
102. Cifuentes G, Bermudez A, Rodriguez R, Patarroyo MA, Patarroyo ME. Shifting the polarity of some critical residues in malarial peptides' binding to host cells is a key factor in breaking conserved antigens' code of silence. Med Chem 2008; 4: 278-292 (Pubitemid 351827303)
103. Fitzmaurice K, Klenerman P. Cellular immunity and acute hepatitis C infection. Curr Pharm Des 2008; 14(17): 1666-1677 (Pubitemid 351998591)
104. Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. Curr Pharm Des 2008; 14(7): 631-640 (Pubitemid 351736442)
105. Supuran CT. Carbonic anhydrases--an overview. Curr Pharm Des 2008; 14(7): 603-614